Evaluation of Surveillance Methods for Staphylococcal Toxic Shock Syndrome

Lindsey Lesher, Aaron DeVries, Richard Danila, and Ruth Lynfield

We compared passive surveillance and International Classification of Diseases, 9th Revision, codes for completeness of staphylococcal toxic shock syndrome (TSS) surveillance in the Minneapolis–St. Paul area, Minnesota, USA. TSS-specific codes identified 55% of cases compared with 30% by passive surveillance and were more sensitive ($p = 0.0005$, McNemar $\chi^2 = 12.25$).

Staphylococcal toxic shock syndrome (TSS) is a severe illness associated with toxin-producing Staphylococcus aureus. First named in 1978, TSS has been associated with tampon use, intravaginal contraceptive devices, and skin infections, particularly after surgical procedures (1,2). In January 1980, the Minnesota Department of Health (MDH) initiated surveillance for TSS with active and passive components. The national incidence of TSS decreased during 1980–1996 (3,4) after removal of high-absorbency tampons from the market and public awareness campaigns. In subsequent years, surveillance methods in Minnesota were changed to a solely passive surveillance system that relied on clinicians to report cases. MDH uses the 1997 case definition of the Centers for Disease Control and Prevention (CDC) (Atlanta, GA, USA) to determine case criteria for any probable TSS case (≥4 clinical criteria and laboratory criteria) considered reportable (Table 1) (5). Given the complexity of the case definition, we suspected that TSS underreporting was likely.

Recently, several factors, including increasing prevalence of community-associated methicillin-resistant S. aureus that carries superantigens and the trend toward earlier menarche, suggested that the incidence of TSS might be increasing (6,7). Additionally, the number of requests for superantigen testing in the Minneapolis–St. Paul (MSP) area made to a reference microbiology laboratory that tests staphylococcal isolates from TSS cases increased during 2000–2003 (8). To determine the incidence of TSS, active surveillance was initiated at all MSP area hospitals using International Classification of Diseases, 9th Revision (ICD-9), codes assigned at hospital discharge. We compared passive surveillance reports with ICD-9 codes to determine an effective and efficient surveillance method for TSS.

The Study

The MSP area is composed of 7 counties with a population of 2,642,056 (2000 US Census) and 24 acute-care hospitals. Requests were sent to medical record departments of these hospitals for data on inpatients discharged from hospitals from January 1, 2000, through December 31, 2003, whose medical records indicated ≥1 of the select ICD-9 study codes. Medical records from all hospitalizations receiving the TSS-specific code (040.82 or 040.89) were reviewed (Figure), and a 20% random sample of medical records from hospitalizations that received ≥1 nonspecific TSS study code (Table 2) from within each hospital was reviewed. Each medical record was reviewed for TSS case criteria and pertinent epidemiologic and clinical information. Additionally, death certificates assigned the ICD-10 code for TSS (A48.3) and cases from the Minnesota Unexplained Critical Illness and Death of Possible Infectious Etiology project (UNEX) (9) during 2000–2003 were reviewed. TSS cases identified through ICD-9 code searches were compared with cases reported to MDH during 2000–2003. Data were analyzed with Stata version 9 (StataCorp, College Station, TX, USA). Statistical analyses included Pearson and McNemar $\chi^2$ tests.

Of 7,414 hospitalizations with ≥1 study code, 116 (1.6%) were assigned the TSS-specific code and were reviewed (Figure). Of the remaining 7,298 hospitalizations assigned ≥1 nonspecific TSS code, 1,575 (21.6%) randomly selected hospitalizations were reviewed. Of these 1,691 hospitalizations, 55 had 5 or 6 criteria for TSS, of which 12 (22%) met the CDC case definition for streptococcal TSS, and 7 were non-MSP residents. The remaining 36 cases were probable or confirmed TSS. No cases from UNEX or death certificate searches met the TSS case definition. Of the 36 TSS cases, 17 (47%) were reported to MDH by passive surveillance. Thirty-one (86%) cases were found by using TSS-specific ICD-9 codes. Five cases were found by using non-TSS–specific ICD-9 codes. After adjusting for 20% random sampling for cases identified by non-TSS–specific codes, we identified the estimated number of cases by using non-TSS–specific codes to be 25. This analysis resulted in 56 estimated TSS cases identified in the surveillance area during 2000–2003 by using ICD-9 codes.

The TSS-specific ICD-9 code search identified 31 of the 56 estimated TSS cases (sensitivity 55%, specificity...
Table 1. Staphylococcal toxic shock syndrome case definitions*

| Criteria | Definition |
|----------|-----------|
| Clinical | Fever: Temperature >38.9°C (102.0°F) |
|          | Rash: Diffuse macular erythrodema |
|          | Desquamation: 1–2 weeks after onset of illness, particularly on the palms and soles |
|          | Hypotension: Systolic blood pressure <90 mm Hg for adults or <5th percentile by age for children <16 years of age; orthostatic decrease in diastolic blood pressure ≥5 mm Hg from lying to sitting, orthostatic syncope, or orthostatic dizziness |
| Multisystem organ involvement† | Gastrointestinal: Vomiting or diarrhea at onset of illness |
|          | Muscular: Severe myalgia or creatine phosphokinase level at least twice the upper limit of normal |
|          | Mucous membrane: Vaginal, oropharyngeal, or conjunctival hyperemia |
|          | Renal: Blood urea nitrogen or creatinine at least twice the upper limit of normal for laboratory or urinary sediment with pyuria (≥5 leukocytes by high-power field) in the absence of urinary tract infection |
|          | Hepatic: Total bilirubin, alanine aminotransferase, or aspartate aminotransferase levels at least twice the upper limit of normal |
|          | Hematologic: Platelet counts ≤100 × 10⁹/L |
|          | Central nervous system: Disorientation or alterations in consciousness with focal neurologic signs when fever and hypotension are absent |
| Laboratory | Culture: If obtained, negative results on blood, throat, or cerebrospinal fluid cultures (blood culture may be positive for *Staphylococcus aureus*) |
|          | Titer: If obtained, no increase in titer for Rocky Mountain spotted fever, leptospirosis, or measles |
| Case classification | Probable: Meets laboratory criteria and in which 4 of 5 clinical findings described above are present |
|          | Confirmed: Meets laboratory criteria and in which all 5 of the clinical findings described above are present, including desquamation, unless the patient dies before desquamation occurs |

*From the US Centers for Disease Control and Prevention (5). †Involving >3 organ systems.

99%). Seventeen cases were reported to MDH by passive surveillance (sensitivity 30%, specificity 99.9%); all were coded with the TSS-specific code. The TSS-specific ICD-9 code search was more sensitive than passive surveillance (p = 0.0005, McNemar χ² 12.25). Of those cases reported to MDH, more were likely to be associated with menstruation (14/17 vs. 5/19; p < 0.001) and to have had a positive test result for *S. aureus* (16/17 vs. 11/19; p = 0.01). Twenty-seven of 36 TSS cases detected had a bacterial culture positive for *S. aureus*. The 3 TSS cases with methicillin-resistant *S. aureus* isolates were not reported to MDH. The positive predictive value of being a case among those coded with the TSS-specific code was 27% (31/116). In 68 of 116 cases that received the TSS-specific code, there was clinical suspicion of TSS, but these cases did not meet the clinical case definition (<5 criteria): 10 were streptococcal TSS and 7 were in non-MSP residents. All 17 cases reported to MDH were detected through the ICD-9 code search.

Conclusions

Surveillance for TSS is challenging given the lack of a diagnostic test and a case definition with multiple components. Under the current passive surveillance system, between one third and half of potential TSS cases were identified. Discrepancies were found in reporting, with menstruation-associated cases more likely to be reported to MDH than nonmenstrual-associated cases. This discrepancy was observed with prior active surveillance efforts (10).

Using ICD-9 codes, we found 12 TSS cases that were of streptococcal etiology. Accuracy may be improved by developing separate ICD-9 codes specific for staphylococcal TSS.

Figure. Flow diagram of toxic shock syndrome (TSS) case ascertainment. TSS cases were identified from International Classification of Diseases, 9th Revision (ICD-9), codes assigned at hospital discharge, cases reported to the Minnesota Unexplained Critical Illness and Death of Possible Infectious Etiology project (UNEX), and death certificate data by using International Classification of Diseases, 10th Revision (ICD-10), code A48.3. MSP, Minneapolis–St. Paul area.
DISPATCHES

Table 2. ICD-9 study codes used for staphylococcal toxic shock syndrome case ascertainment*

| Code         | Associated diagnosis               |
|--------------|-----------------------------------|
| 040.89 or 040.82† | Toxic shock syndrome              |
| 038.11†     | Staphylococcus aureus septicemia   |
| 038.12†     | Other staphylococcal septicemia    |
| 038.9        | Unspecified sepsis                 |
| 785.50       | Shock without mention of trauma    |
| 785.59 or 785.52† | Sepsis                           |

*ICD-9, International Classification of Diseases, 9th Revision.
†The code assigned to toxic shock syndrome changed from 040.89 to 040.82 on October 1, 2002, and the code assigned to sepsis changed from 785.59 to 785.52 on October 1, 2003. Although the codes changed, their associated diagnoses remained unchanged and are considered mutually exclusive.
‡Code eliminated after interim analysis of 627 medical records at 14 of 24 hospitals. Of 122 records receiving only this code, 40% had 0 case criteria, all had ≤3 criteria, and 88% had bacteremia with a staphylococcal species other than S. aureus.

References

1. Reingold AL, Hargrett NT, Dan BB, Shands KN, Strickland BY, Broome CV. Nonmenstrual toxic shock syndrome: a review of 130 cases. Ann Intern Med. 1982;96:871–4.
2. Kain KC, Schulzer M, Chow AW. Clinical spectrum of nonmenstrual toxic shock syndrome (TSS): comparison with menstrual TSS by multivariate discriminant analyses. Clin Infect Dis. 1993;16:100–6.
3. Gaventa S, Reingold AL, Hightower AW, Broome CV, Schwartz B, Hoppe C, et al. Active surveillance for toxic shock syndrome in the United States. 1986. Rev Infect Dis. 1989;11(Suppl 1):S28–34.
4. Hajjeh RA, Reingold A, Weil A, Shutt K, Schuchat A, Perkins BA. Toxic shock syndrome in the United States: surveillance update, 1979–1996. Emerg Infect Dis. 1999;5:807–10.
5. Centers for Disease Control and Prevention. Toxic shock syndrome 1997 case definition [cited 2005 Oct 5]. Available from http://www.cdc.gov/epo/dphsi/casedef/toxicsscurrent.htm
6. McDowell MA, Droyd DJ, Hughes JP. Has age at menarche changed? Results from the National Health and Nutrition Examination Survey (NHANES) 1999–2004. J Adolesc Health. 2007;40:227–31. DOI: 10.1016/j.jadohealth.2006.10.002
7. Euling SY, Herman-Giddens ME, Lee PA, Selevan SG, Juul A, Sorensen TI, et al. Examination of US puberty-timing data from 1940 to 1994 for secular trends: panel findings. Pediatrics. 2008;121:S172–91. DOI: 10.1542/peds.2007-1813D
8. Schlievert PM, Tripp TJ, Peterson ML. Reemergence of staphylococcal toxic shock syndrome in Minneapolis–St. Paul, Minnesota, during the 2000–2003 surveillance period. J Clin Microbiol. 2004;42:2875–6. DOI: 10.1128/JCM.42.6.2875-2876.2004
9. Hajjeh RA, Relman D, Cieslak PR, Sofair AN, Passaro D, Flood J, et al. Surveillance for unexplained deaths and critical illnesses due to possibly infectious causes, United States, 1995–1998. Emerg Infect Dis. 2002;8:145–53.

cause of changes in bacterial virulence characteristics, host characteristics such as the use of new devices or products, changes in human behavior, or changes in host susceptibility. Evaluation of this approach in other areas to assess sensitivity of TSS surveillance would be useful because coding practices may differ.

Acknowledgments

We thank Brenda Jewel, Craig Morin, Jean Rainbow, and Lori Triden for assistance with data collection; Elly Pretzel for graphics assistance; and Catherine Lexau and Tyson Rogers for statistical assistance.

This study was supported by grants from the National Institutes of Health (Ruth L. Kirschstein National Research Service Award T32 AI 055433–2), the Loan Repayment Program, the National Institute of Allergy and Infectious Disease (Extramural Clinical Research L30 AI 071582-01), and the Centers for Disease Control and Prevention (Emerging Infections Program CDC 5 R01 CI000209).

Ms Lesher is an epidemiologist in the Emerging Infections Program at the Minnesota Department of Health. Her research interests include epidemiologic methods and disease caused by S. aureus.
10. Osterholm MT, Forfang JC. Toxie-shock syndrome in Minnesota: results of an active-passive surveillance system. J Infect Dis. 1982;145:458–64.

11. Lazarus R, Klompas M, Campion FX, McNabb SJ, Hou X, Daniel J, et al. Electronic support for public health: validated case finding and reporting of notifiable diseases using electronic medical data. J Am Med Inform Assoc. 2009;16:18–24. DOI: 10.1197/jamia.M2848

Address for correspondence: Lindsey Lesher, Minnesota Department of Health, 625 Robert St N, PO Box 64975, St. Paul, MN 55164-0975, USA; email: lindsey.lesher@state.mn.us

Use of trade names is for identification only and does not imply endorsement by the Public Health Service or by the U.S. Department of Health and Human Services.